(AGL) agilon health - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00857U1079
AGL: Primary Care, Healthcare Services, Senior Care
Agilon Health Inc (NYSE:AGL) stands out as a leader in the senior healthcare sector, leveraging a unique business model that empowers primary care physicians to deliver high-quality, patient-centric care. Their approach revolves around a subscription-like model, where they manage the comprehensive healthcare needs of seniors on a per-member, per-month basis. This structure aligns incentives, ensuring that providers focus on preventive care and better health outcomes.
The companys business model is rooted in value-based care, emphasizing long-term relationships with physicians and risk-sharing arrangements. By partnering with local medical groups, Agilon equips them with the resources and infrastructure needed to manage patient populations effectively. This model not only enhances care quality but also creates a scalable platform poised for growth in the expanding Medicare Advantage market.
With the U.S. population aging and healthcare costs rising, Agilon is strategically positioned to capitalize on these trends. The growing demand for cost-effective, high-quality care for seniors underscores the companys market opportunity. Their focus on value-based care aligns with broader industry shifts, making them a compelling option for investors seeking exposure to the healthcare sectors evolving landscape.
From a financial perspective, Agilon Health offers an intriguing narrative. As a publicly traded company with a market capitalization of approximately $1.4 billion, they present a balance of growth potential and operational scale. Their forward P/E of ~178.57 reflects market expectations for significant revenue growth, while their price-to-sales ratio of 0.25 suggests a reasonable valuation relative to their revenue generation.
Investors and fund managers considering Agilon should focus on their ability to scale their partnerships with physician groups and their success in managing medical costs within their risk-sharing arrangements. Additionally, their strategy to enhance patient outcomes through data-driven insights and integrated care management positions them well in the competitive healthcare services landscape.
Additional Sources for AGL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AGL Stock Overview
Market Cap in USD | 1,447m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2021-04-15 |
AGL Stock Ratings
Growth 5y | -79.8% |
Fundamental | -30.7% |
Dividend | 0.0% |
Rel. Strength Industry | -23.2 |
Analysts | 3.13/5 |
Fair Price Momentum | 3.24 USD |
Fair Price DCF | - |
AGL Dividends
No Dividends PaidAGL Growth Ratios
Growth Correlation 3m | 80.1% |
Growth Correlation 12m | -72% |
Growth Correlation 5y | -89.4% |
CAGR 5y | -40.50% |
CAGR/Max DD 5y | -0.42 |
Sharpe Ratio 12m | -0.04 |
Alpha | -22.14 |
Beta | -0.71 |
Volatility | 73.21% |
Current Volume | 7035.6k |
Average Volume 20d | 6562.9k |
As of March 15, 2025, the stock is trading at USD 4.05 with a total of 7,035,582 shares traded.
Over the past week, the price has changed by +15.38%, over one month by +18.42%, over three months by +84.93% and over the past year by -22.56%.
Probably not. Based on ValueRay Fundamental Analyses, agilon health (NYSE:AGL) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -30.74 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AGL as of March 2025 is 3.24. This means that AGL is currently overvalued and has a potential downside of -20%.
agilon health has received a consensus analysts rating of 3.13. Therefor, it is recommend to hold AGL.
- Strong Buy: 2
- Buy: 1
- Hold: 18
- Sell: 2
- Strong Sell: 0
According to ValueRays Forecast Model, AGL agilon health will be worth about 3.5 in March 2026. The stock is currently trading at 4.05. This means that the stock has a potential downside of -13.58%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3.6 | -12.1% |
Analysts Target Price | 2.9 | -28.6% |
ValueRay Target Price | 3.5 | -13.6% |